The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
The FDA said on Monday it has authorized the first over-the-counter flu and COVID-19 combination test for the public to use ...
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...
Sept. 18, 2024 – The FDA has approved an injectable form of the cancer drug atezolizumab in combination with the enzyme hyaluronidase for use in patients with certain types of cancers of the ...
A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...
People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the first "self-administered" influenza vaccine — though a delay in the ...
No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...
26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA ...
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first vaccine ...
Sept. 26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday. The drug, generically called Cobenfy, is the first oral ...